Raphael TERREUX
Equipe : Groupe EcMo
Courriel : raphael.terreux@ibcp.fr
Téléphone : +33(0)4-37-65-29-43
Statut : Professeur
58 publications au total. Seules les 5 dernières années sont affichées
2025
58. Rhodamine6G and Hœchst33342 narrow BmrA conformational spectrum for a more efficient use of ATP.
Gobet A, Moissonnier L, Zarkadas E, Magnard S, Bettler E, Martin J, Terreux R, Schoehn G, Orelle C, Jault Jm, Falson P, Chaptal V
(2025) Nat Commun 16 :1745-1745
57. Author Correction: Pharmacogenomic screening identifies and repurposes leucovorin and dyclonine as pro-oligodendrogenic compounds in brain repair.
Huré Jb, Foucault L, Ghayad Lm, Marie C, Vachoud N, Baudouin L, Azmani R, Ivljanin N, Arevalo-nuevo A, Pigache M, Bouslama-oueghlani L, Chemelle Ja, Dronne Ma, Terreux R, Hassan B, Gueyffier F, Raineteau O, Parras C
(2025) Nat Commun 16 :538-538
2024
56. Design, synthesis, and structure-activity relationship studies of 6H-benzo[b]indeno[1,2-d]thiophen-6-one derivatives as DYRK1A/CLK1/CLK4/haspin inhibitors.
Faouzi A, Arnaud A, Hallé F, Roussel J, Aymard M, Denavit V, Do Cv, Mularoni A, Salah M, Elhady A, Pham Tn, Bancet A, Le Borgne M, Terreux R, Barret R, Engel M, Lomberget T
(2024) Rsc Med Chem 16 :179-199
55. Pharmacogenomic screening identifies and repurposes leucovorin and dyclonine as pro-oligodendrogenic compounds in brain repair.
Huré Jb, Foucault L, Ghayad Lm, Marie C, Vachoud N, Baudouin L, Azmani R, Ivljanin N, Arevalo-nuevo A, Pigache M, Bouslama-oueghlani L, Chemelle Ja, Dronne Ma, Terreux R, Hassan B, Gueyffier F, Raineteau O, Parras C
(2024) Nat Commun 15 :9837-9837
2023
54. Induction of a strong and long-lasting neutralizing immune response by dPreS1-TLR2 agonist nanovaccine against hepatitis B virus.
Lamrayah M, Charriaud F, Desmares M, Coiffier C, Megy S, Colomb E, Terreux R, Lucifora J, Durantel D, Verrier B
(2023) Antiviral Res 209 :105483-105483
2021
53. Discovery of a Novel Non-Narcotic Analgesic Derived from the CL-20 Explosive: Synthesis, Pharmacology, and Target Identification of Thiowurtzine, a Potent Inhibitor of the Opioid Receptors and the Ion Channels.
Aguero S, Megy S, Eremina Vv, Kalashnikov Ai, Krylova Sg, Kulagina Da, Lopatina Ka, Fournier M, Povetyeva Tn, Vorozhtsov Ab, Sysolyatin Sv, Zhdanov Vv, Terreux R
(2021) Acs Omega 6 :15400-15411
52. Latent TGF-β Activation Is a Hallmark of the Tenascin Family.
Aubert A, Mercier-gouy P, Aguero S, Berthier L, Liot S, Prigent L, Alcaraz Lb, Verrier B, Terreux R, Moali C, Lambert E, Valcourt U
(2021) Front Immunol 12 :613438-613438
51. Surface charge modulation of rifampicin-loaded PLA nanoparticles to improve antibiotic delivery in Staphylococcus aureus biofilms.
Da Costa D, Exbrayat-héritier C, Rambaud B, Megy S, Terreux R, Verrier B, Primard C
(2021) J Nanobiotechnology 19 :12-12
50. Uncompetitive nanomolar dimeric indenoindole inhibitors of the human breast cancer resistance pump ABCG2.
Guragossian N, Belhani B, Moreno A, Nunes Mt, Gonzalez-lobato L, Marminon C, Berthier L, Rocio Andrade Pires Ad, Özvegy-laczka C, Sarkadi B, Terreux R, Bouaziz Z, Berredjem M, Jose J, Di Pietro A, Falson P, Le Borgne M
(2021) Eur J Med Chem 211 :113017-113017
2020
49. Construction of atomic models of full hepatitis B vaccine particles at different stages of maturation.
Berthier L, Brass O, Deleage G, Terreux R
(2020) J Mol Graph Model 98 :107610-107610
48. Molecular Dynamics Studies of Poly(Lactic Acid) Nanoparticles and Their Interactions with Vitamin E and TLR Agonists Pam1CSK4 and Pam3CSK4.
Megy S, Aguero S, Da Costa D, Lamrayah M, Berthet M, Primard C, Verrier B, Terreux R
(2020) Nanomaterials (basel) 10 :
